<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312973</url>
  </required_header>
  <id_info>
    <org_study_id>17767</org_study_id>
    <secondary_id>2014-003292-31</secondary_id>
    <nct_id>NCT02312973</nct_id>
  </id_info>
  <brief_title>To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects</brief_title>
  <official_title>Investigation of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Oral Doses of 75 mg Molidustat in Male and Female Subjects With Renal Impairment Requiring Hemo- or Peritoneal Dialysis Compared to Age- and Weight-matched Healthy Subjects in a Single-center, Non-controlled, Non-blinded Study With Group Stratification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the pharmacokinetics (absorption, distribution, elimination) of
      molidustat after intake of a single 75 mg tablet in subjects with renal impairment requiring
      hemo- or peritoneal dialysis compared to age-and gender-matched healthy subjects. In
      addition, the effect of molidustat on the hormone erythropoietin will be evaluated as well as
      the safety and tolerability of molidustat.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics characterized by Cmax of Molidustat</measure>
    <time_frame>Up to 96 hours post dose</time_frame>
    <description>Cmax: maximum drug concentration in plasma after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics characterized by AUC of Molidustat</measure>
    <time_frame>Up to 96 hours post dose</time_frame>
    <description>AUC: area under the plasma concentration vs time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics characterized by Cmax,norm of Molidustat</measure>
    <time_frame>Up to 96 hours post dose</time_frame>
    <description>Cmax,norm;maximum drug concentration in plasma after single dose administration divided by dose (milligrams) per kilogram body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics characterized by (AUCnorm) of Molidustat</measure>
    <time_frame>Up to 96 hours post dose</time_frame>
    <description>AUCnorm; area under the plasma concentration vs time curve divided by dose per kg body weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics characterized by Cmax of erythropoietin</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Cmax: maximum drug concentration in plasma after single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics characterized by AUC (0-tlast) of erythropoietin</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>AUC(0-tlast): AUC from time 0 to the last data point above lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics characterized by tmax of erythropoietin</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>tmax: time to reach maximum drug concentration in plasma after single (first) dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to 7 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 75 mg molidustat (fasted) in subjects on hemodialysis (at start of hemodialysis and on a hemodialysis free day,respectively)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 75 mg molidustat (fasted) in subjects on peritoneal dialysis (after start of peritoneal dialysis intervall and, optionally, after the start of a peritoneal dialysis-free intervall,respectively)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 75 mg molidustat (fasted) in healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molidustat(BAY85-3934)</intervention_name>
    <description>Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molidustat(BAY85-3934)</intervention_name>
    <description>One single oral dose of 75 mg molidustat in healthy subjects</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female (without childbearing potential)

          -  Age: ≥18 and ≤79 years of age

          -  Body mass index (BMI): ≥18 and ≤34 kg/m2

          -  Ethnicity: White

          -  Subjects with severe renal impairment on hemodialysis or peritoneal dialysis, and

          -  Healthy subjects

        Exclusion Criteria:

          -  Women of childbearing potential, pregnant or lactating women

          -  Use of medication within the 2 weeks preceding the study which could interfere with
             the investigational product

          -  Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus
             antibodies (HCV Ab), human immune deficiency virus 1 and 2 antibodies (HIV 1/2 Ab)

          -  Exclusion periods from other studies or simultaneous participation in other clinical
             studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Velbert</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

